PGL suspends its phase III trial for PI-88 today and the share price dropped more than $0.62 to close at $0.58, more than 50% drop. For a biotech to fail a trial at such late stage, it will no doubt bring on these dramatic fall in its share price.
We should have seen this coming - see:
http://ozstock.blogspot.com/2008/07/company-brief-pgl-progen.html
